Taysha Gene Therapies (TSHA) Earnings Analysis
Taysha Gene Therapies (TSHA) has no confirmed upcoming earnings date. Last quarter (2026-03-19) it beat with EPS -0.08 USD vs -0.11 USD est (+27.3%). It has beaten estimates in 4/4 recent quarters (100%). Trailing P/E -14.79.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does TSHA next report earnings?
No confirmed upcoming earnings date is currently scheduled for TSHA. This page updates as the calendar is published.
TSHA earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-19 | -0.08 USD | -0.11 USD | +27.3% | Beat |
| 2025-05-15 | -0.08 USD | -0.08 USD | 0% | Beat |
| 2025-02-26 | -0.07 USD | -0.08 USD | +12.5% | Beat |
| 2024-08-12 | -0.09 USD | -0.1 USD | +10% | Beat |
Beat rate: 4/4 (100%) over reported quarters with consensus data.
TSHA valuation and analyst view
| Trailing P/E | -14.79 |
|---|---|
| Trailing EPS | -0.35424 USD |
| Price / book | 9.79 |
| Dividend yield | 0.00% |
| Market cap | 1.40B |
| Analyst consensus | Buy (15 buy / 3 hold / 0 sell) |
| Avg price target | 14 USD |
Related research pages
Frequently asked questions
When is Taysha Gene Therapies (TSHA)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for TSHA. This page updates as the calendar is published.
Did TSHA beat earnings last quarter?
In its 2026-03-19 report, TSHA posted EPS of -0.08 USD versus a -0.11 USD estimate — a beat of 27.3%.
What is TSHA's earnings track record?
Over the last 4 reported quarters with consensus data, TSHA beat estimates 4 times (100%).
What is TSHA's current P/E ratio and EPS?
TSHA trades at a trailing P/E of -14.79 on trailing EPS of -0.3542399628061674 USD.
What do analysts rate TSHA?
Analyst consensus is "Buy" across 18 ratings (0 strong buy, 15 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 14 USD.